Empowering BGSi's Vision for Precision Medicine
The Biomedical and Genome Science Institute (BGSi) is leading an initiative to advance precision medicine in Indonesia using population biobanking and genomic sequencing
Product Used
- Pharmacogenomics (PGx)
- Clinical Decision System (CDS)
Organization
BB Binomika of Indonesia's Ministry of Health
Sample Size
10,000 reports
Location
Indonesia
Background
The Biomedical and Genome Science Institute (BGSi), led by BB Binomika of Indonesia's Ministry of Health, drives precision medicine nationwide. Using population biobanking and genomic sequencing, BGSi delivers personalized healthcare tailored to Indonesia's diverse population. In collaboration with BGSi, NalaGenetics leverages AWS to deploy pharmacogenomic (PGx) reports via a Clinical Decision Support platform. This secure, scalable solution generates PGx reports for over 10,000 participants, enabling healthcare providers to personalize treatments and improve patient outcomes.
Challenges
A large portion of the population has genetic information that could improve healthcare decisions, yet nearly 90% remains underutilized due to a lack of personalized approaches. This leads to ineffective treatments, adverse drug reactions, and higher healthcare costs. To address these issues and better leverage genetic data across Indonesia, several key challenges must be overcome:
Genetic Diversity
Indonesia's genetic diversity requires tailored approaches to medication based on varying genetic responses.
Scalable Reporting
The need for a locally deployed platform to generate accurate and secured PGx reports for a large population.
Access to Reports
Ensuring healthcare providers can easily access PGx reports for personalized treatment decisions.
Our Solutions
To address the challenges of using genetic information in healthcare across Indonesia, we use Nala Clinical Decision Support™ (CDS). Nala CDS is a patented software that securely interprets genetic data, integrating pharmacogenomic (PGx) insights into healthcare workflows. Built to ISO standards, it provides real-time, actionable information for personalized treatment decisions and reduces the risks of adverse drug reactions. To further enhance CDS, we've integrated the following solutions:
Secure Local Data Retention
We used AWS to ensure secure local data retention and compliance with Indonesia's privacy regulations, deploying the PGx reports via Elastic Container Registry (ECR).
Scalable Reporting Platform
AWS infrastructure enabled scalable reporting for over 10,000 participants, ensuring efficient data processing and accessibility as the project grows.
Customized Reports
We customized PGx reports for better patient understanding, enabling healthcare providers to make precise, personalized treatment decisions.
Real-Time Data Access
AWS allows for real-time report generation and access, optimizing healthcare workflows and enhancing patient care.
Outcomes and Ongoing Impact
As the project progresses, NalaGenetics and BGSi aim to:
Utilize and Evaluate
Assess the adoption and clinical outcomes of pre-emptive PGx testing among participants.
Cost-Effectiveness Study
Conduct research to evaluate the economic benefits of pre-emptive PGx testing for the Indonesian population.
Interoperability Development
Create a playbook to guide genetic testing providers in issuing PGx reports via the SatuSehat platform.
“In particular, NalaGenetics has played a pivotal role in supporting BGSi by providing access to its pharmacogenomics bioinformatics pipeline for the analysis of Indonesia's first 10K genomes. This pipeline is seamlessly integrated with BGSi's Amazon Web Services (AWS) genome data infrastructure, ensuring a robust and efficient system for managing, analyzing genomic data and returning results to participants of BGSi. Nalagenetics has gone above and beyond by ensuring compliance with Indonesian regulations, which mandate that genomic data must be securely stored and analyzed within the country”
Indri Rooslamiati, M.Sc., Apt
Acting Director of National Biomedical and Genome Science Institute (BGSi) and Head of BB Binomika, Ministry of Health of Republic of Indonesia
Read more customer stories
Transforming Clinical Practice with PRECISE-CIP: A Patient-Facing Solution
Discover How Our Solutions Can Benefit Your Initiative
At NalaGenetics, we empower initiatives with scalable solutions that drive lasting public health impact. Ready to enhance your healthcare services? Connect with us today!
